Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Min Hee Hong

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

M.H. Hong1, S. Shin2, Y. Choi3, B.C. Cho1, H.R. Kim1

Author affiliations

  • 1 Department Of Internal Medicine, Yonsei Cancer Center Yonsei University, 03799 - Seoul/KR
  • 2 Department Of Pathology, College of Medicine, Hanyang University, 04763 - Seoul/KR
  • 3 Department Of Pathology, Samsung Medical Center, 06351 - Seoul/KR
More

Resources

Abstract 3319

Background

The prognosis of advanced esophageal squamous cell carcinoma (ESCC) is extremely poor. With an increasing potential of immune checkpoints modulators in oncology, the aim of the current study was to assess the extent of tumor-infiltrating lymphocyte (TIL) and expression and significance of various immune checkpoints in the resected ESCC.

Methods

Total 396 patients who underwent radical surgery for ESCC between 2005 and 2013 were included. Using immunohistochemistry (IHC) with tissue microarray, type of T-cells including CD3, CD8, and Foxp3 T-cell and the expression of checkpoints including programmed cell death-ligand 1 (PD-L1), programmed cell death-1 (PD-1), inducible co-stimulator (ICOS), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and mucin-dominant containing-3 (TIM-3) was manually scored. Outcome measures included recurrence-free survival (RFS) and overall survival (OS). The expression was defined as high density when the expression level was above the median value/4HPFs (high-power fields).

Results

With median follow-up period of 24.8 months, 32.6% of recurrence and 45.7% of death occurred. Patients with a high frequency of CD3+ TILs (n = 198) demonstrated a significant longer RFS (hazard ratio [HR] = 0.61, P = 0.0005) and OS (HR = 0.59, P = 0.0005). High ICOS expression group (n = 184) displayed longer RFS (HR = 0.72, P = 0.021) and OS (HR = 0.67, P = 0.007) than low ICOS expression group. Regarding PD-1 expression, the RFS (HR = 0.67, P = 0.004) and OS (HR = 0.66, P = 0.006) were significantly better in high expression group (n = 179). In multivariate Cox analyses, high CD3+ TIL and ICOS were also indicated as an independent prognostic factor for better PFS (HR = 0.59, P < 0.001 and HR = 0.64, P = 0.002, respectively) and OS (HR = 0.48, P < 0.001 and HR = 0.60, respectively) and high TIM-3 expression in immune cells was related to the shorter RFS (HR = 1.46, P = 0.020) and OS (HR = 1.54, P = 0.013). Even though various cut-off applied, the expression of PD-L1 in tumor or immune cells failed to report any association with prognosis.

Conclusions

Our analysis involving TMA and IHC of multiple immune checkpoints in resected ESCC suggests that CD3+ TILs and ICOS+ T-cells might be a favorable prognostic factor.

Clinical trial identification

Legal entity responsible for the study

Min Hee Hong.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings